Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 03 04:00PM ET
1.96
Dollar change
+0.14
Percentage change
7.69
%
IndexRUT P/E- EPS (ttm)-0.88 Insider Own1.05% Shs Outstand196.22M Perf Week19.51%
Market Cap384.59M Forward P/E10.79 EPS next Y0.18 Insider Trans-1.17% Shs Float194.16M Perf Month7.69%
Income-98.50M PEG- EPS next Q-0.17 Inst Own72.42% Short Float19.62% Perf Quarter-20.00%
Sales277.79M P/S1.38 EPS this Y87.85% Inst Trans4.83% Short Ratio8.83 Perf Half Y-36.98%
Book/sh-1.77 P/B- EPS next Y173.65% ROA-33.56% Short Interest38.09M Perf Year102.65%
Cash/sh0.96 P/C2.03 EPS next 5Y16.90% ROE- 52W Range0.70 - 3.40 Perf YTD-34.45%
Dividend Est.- P/FCF- EPS past 5Y23.09% ROI-55.65% 52W High-42.35% Beta0.97
Dividend TTM- Quick Ratio1.49 Sales past 5Y7.64% Gross Margin81.80% 52W Low180.00% ATR (14)0.13
Dividend Ex-Date- Current Ratio1.97 EPS Y/Y TTM70.21% Oper. Margin6.50% RSI (14)61.36 Volatility7.79% 6.58%
Employees240 Debt/Eq- Sales Y/Y TTM215.98% Profit Margin-35.46% Recom1.71 Target Price7.59
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q28.24% Payout- Rel Volume1.43 Prev Close1.82
Sales Surprise55.46% EPS Surprise-91.75% Sales Q/Q186.33% EarningsAug 12 BMO Avg Volume4.32M Price1.96
SMA2014.62% SMA504.81% SMA200-13.62% Trades Volume6,152,572 Change7.69%
Date Action Analyst Rating Change Price Target Change
Jun-20-24Downgrade BofA Securities Neutral → Underperform $2.50
Jan-03-24Downgrade BofA Securities Buy → Neutral
Nov-20-23Resumed JP Morgan Neutral
Aug-01-23Upgrade Northland Capital Under Perform → Market Perform
Jun-15-23Upgrade BofA Securities Underperform → Buy $1.25 → $4
Mar-16-23Downgrade Northland Capital Market Perform → Under Perform $1
Mar-16-23Downgrade BofA Securities Neutral → Underperform $8 → $1.50
Mar-07-23Upgrade Credit Suisse Underperform → Neutral $6.50 → $7
Feb-27-23Resumed BofA Securities Neutral $8
Feb-24-23Upgrade Jefferies Hold → Buy $12
Today 04:56AM
Oct-02-24 08:00AM
Sep-25-24 04:30PM
Sep-11-24 11:30AM
Sep-05-24 08:00AM
08:00AM Loading…
Sep-03-24 08:00AM
Aug-26-24 08:00AM
Aug-13-24 01:06AM
Aug-12-24 11:44AM
07:10AM
06:09AM
06:00AM
Aug-07-24 04:30PM
Aug-05-24 10:00AM
Jul-25-24 08:00AM
08:00AM Loading…
Jul-24-24 08:00AM
Jul-16-24 08:00AM
Jun-28-24 07:49AM
07:00AM
Jun-13-24 02:31PM
Jun-11-24 10:00AM
Jun-06-24 11:31AM
May-23-24 12:11PM
09:00AM
May-22-24 08:00AM
May-20-24 10:30AM
06:00AM
May-14-24 08:00AM
May-10-24 04:00PM
May-08-24 12:20PM
11:08AM Loading…
11:08AM
03:04AM
May-07-24 12:20PM
10:55AM
08:55AM
08:22AM
07:39AM
07:36AM
07:15AM
06:11AM
06:00AM
Apr-29-24 08:00AM
Apr-23-24 08:00AM
Apr-21-24 10:39AM
Apr-07-24 02:45PM
Apr-01-24 08:00AM
Mar-28-24 11:30AM
Mar-26-24 08:00AM
Mar-25-24 04:00PM
Mar-22-24 06:26PM
03:10PM
11:04AM
Mar-04-24 08:28PM
Feb-28-24 08:34AM
07:41AM
Feb-27-24 09:38PM
07:53AM
07:20AM
06:25AM
06:00AM
03:30AM
Feb-16-24 04:30PM
Feb-15-24 03:13AM
Feb-13-24 10:00AM
08:00AM
Feb-01-24 02:00PM
Jan-23-24 04:00PM
Jan-19-24 08:50AM
Jan-18-24 09:15PM
04:00PM
Jan-03-24 07:00AM
Dec-18-23 08:00AM
Dec-13-23 04:00PM
Dec-07-23 11:30AM
Nov-13-23 10:30AM
Nov-11-23 11:00AM
Nov-09-23 04:30PM
Nov-08-23 01:16PM
11:04AM
Nov-07-23 08:19AM
07:15AM
06:06AM
06:00AM
Nov-01-23 10:01AM
Oct-31-23 08:00AM
Oct-24-23 08:00AM
Sep-12-23 10:15AM
Aug-31-23 11:31AM
Aug-28-23 08:00AM
Aug-26-23 11:00AM
Aug-11-23 08:00AM
Aug-08-23 04:15PM
Aug-06-23 08:06AM
Aug-02-23 09:06AM
Aug-01-23 07:15AM
06:05AM
06:00AM
Jul-24-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 06:00AM
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Koenig Sheldon L.President and CEOSep 17 '24Sale1.8014,55026,132752,266Sep 18 04:12 PM
Warren EricChief Commercial OfficerSep 17 '24Sale1.782,6084,650162,659Sep 18 04:11 PM
Foody Joanne M.OfficerSep 17 '24Proposed Sale1.783,3816,015Sep 17 04:02 PM
Warren EricOfficerSep 17 '24Proposed Sale1.782,6084,651Sep 17 03:28 PM
Koenig Sheldon L.OfficerSep 17 '24Proposed Sale1.8014,55026,133Sep 17 03:20 PM
Warren EricChief Commercial OfficerAug 19 '24Sale1.95211411165,267Aug 20 04:03 PM
Warren EricOfficerAug 19 '24Proposed Sale1.95211410Aug 19 03:50 PM
Warren EricChief Commercial OfficerJul 17 '24Sale2.59108279165,478Jul 19 08:30 AM
Foody Joanne M.Chief Medical OfficerJul 17 '24Sale2.609172,383272,862Jul 19 08:29 AM
Foody Joanne M.Chief Medical OfficerJun 18 '24Sale2.873,2859,418273,779Jun 20 04:20 PM
Warren EricChief Commercial OfficerJun 18 '24Sale2.862,5407,254165,586Jun 20 04:16 PM
Warren EricChief Commercial OfficerMay 17 '24Sale2.48192477168,126May 20 04:14 PM